{
    "clinical_study": {
        "@rank": "38519", 
        "acronym": "DOXY-HF", 
        "arm_group": [
            {
                "arm_group_label": "Doxycycline 100 mg", 
                "arm_group_type": "Experimental", 
                "description": "Doxycycline 100 mg twice daily for 14 days"
            }, 
            {
                "arm_group_label": "Doxycycline 20 mg", 
                "arm_group_type": "Experimental", 
                "description": "Doxycycline 20 mg twice daily for 14 days"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "Non-ischemic cardiomyopathy and heart failure are highly influenced by the presence of\n      systemic inflammation.\n\n      Doxycycline is a FDA-approved drug to treat bacterial infections which also shows powerful\n      anti-inflammatory effects.\n\n      In this study we plan to determine the effects of Doxycycline in patients with stable heart\n      failure and non-ischemic cardiomyopathy on peak of aerobic exercise capacity (peak V02) and\n      ventilator efficiency measured with a cardiopulmonary test."
        }, 
        "brief_title": "Safety and Efficacy of Doxycycline in Patients With Non-Ischemic Cardiomyopathy", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Non-ischemic Cardiomyopathy", 
            "Systolic Heart Failure (NYHA II-III)"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Heart Failure", 
                "Cardiomyopathies", 
                "Heart Failure, Systolic"
            ]
        }, 
        "detailed_description": {
            "textblock": "In this study of Safety and Efficacy of Doxycycline in Patients with Non-Ischemic\n      Cardiomyopathy Population, we will enroll 24 patients with a clinical diagnosis of heart\n      failure and non-ischemic cardiomyopathy (recent imaging study documenting LV ejection\n      fraction <50%, and no history of coronary or ischemic heart disease) in a single-center,\n      randomized, double-blinded, placebo-controlled clinical trial with allocation 1:1:1 to\n      Doxycycline 100 mg twice daily or Doxycycline 20 mg twice daily or Placebo for 2 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Non-ischemic cardiomyopathy (LVEF<40%)\n\n          -  Heart failure NYHA II-III\n\n        Exclusion Criteria:\n\n          -  Age <18\n\n          -  Recent changes (previous 3 months) in HF maintenance medications (beta-blockers,\n             angiotensin converting enzyme   [ACE] inhibitors, aldosterone antagonists,\n             vasodilators, cardiac glycosides, diuretics)\n\n          -  Hospitalization for worsening HF or acute decompensated HF within the previous 12\n             months\n\n          -  History of coronary or ischemic heart disease\n\n          -  Anticipated need for cardiac resynchronization therapy (CRT) or automated-implantable\n             cardioverter defibrillator (AICD) or coronary revascularization or cardiac surgery\n\n          -  Angina or electrocardiograph (ECG) changes that limit maximum exertion during\n             cardiopulmonary exercise testing\n\n          -  Active infection including chronic infection\n\n          -  Active cancer (or prior diagnosis of cancer within the past 10 years)\n\n          -  Recent (<14 days) use of anti-inflammatory drugs (not including NSAIDs), Chronic\n             inflammatory disorder (including but not limited to rheumatoid arthritis, systemic\n             lupus erythematosus), malignancy, or any comorbidity limiting survival or ability to\n             complete the study\n\n          -  Pregnancy\n\n          -  Inability to give informed consent\n\n          -  Other conditions limiting completion of cardiopulmonary exercise test or completion\n             of the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01935622", 
            "org_study_id": "VCU HM14393"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Doxycycline 100 mg", 
                    "Doxycycline 20 mg"
                ], 
                "intervention_name": "Doxycycline", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Doxycycline", 
                "Doxycycline hyclate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "heart failure", 
            "non-ischemic cardiomyopathy"
        ], 
        "lastchanged_date": "September 4, 2013", 
        "location": {
            "contact": {
                "email": "aabbate@vcu.edu", 
                "last_name": "Antonio Abbate"
            }, 
            "facility": {
                "address": {
                    "city": "Richmond", 
                    "country": "United States", 
                    "state": "Virginia", 
                    "zip": "23298"
                }, 
                "name": "Virginia Commonwealth University"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Phase II Study of Safety and Efficacy of Doxycycline in Patients With Non-Ischemic Cardiomyopathy", 
        "overall_contact": {
            "email": "aabbate@vcu.edu", 
            "last_name": "Antonio Abbate"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Virginia Commonwealth University IRB"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Interval change in peak VO2 measured at cardiopulmonary test", 
            "measure": "Peak aerobic exercise capacity", 
            "safety_issue": "Yes", 
            "time_frame": "14 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01935622"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Virginia Commonwealth University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Virginia Commonwealth University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}